DAP12 and the host response to cryptococcosis

DAP12 和宿主对隐球菌病的反应

基本信息

  • 批准号:
    10449347
  • 负责人:
  • 金额:
    $ 57.18万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-07-12 至 2026-06-30
  • 项目状态:
    未结题

项目摘要

Project Summary Cryptococcus neoformans is an opportunistic fungal pathogen that is inhaled into the lungs and can disseminate to the brain, causing a highly fatal meningoencephalitis in immunocompromised patients, particularly those with HIV/AIDS, solid organ transplantation, and cancer. Even with contemporary combination antifungal therapy, the mortality rate for cryptococcosis approximates 25%, and the at-risk population is expanding with the development of new immunosuppressive regimens for autoimmunity and cancer. Our ability to develop new treatments for cryptococcosis remains limited because we do not yet fully understand how the fungus evades host immunity. We recently discovered that C. neoformans is able to suppress the response of inflammatory monocytes, innate immune cells that give rise to macrophages and dendritic cells and typically aid in fungal recognition and clearance by the host. C. neoformans directs inflammatory monocytes to differentiate into alternatively activated (M2) macrophages that are permissive for fungal proliferation and dissemination, leading to increased mortality from the infection. We have identified a signaling adapter DNAX- activating protein of 12 kDa (DAP12) that may play a crucial role in suppressing the inflammatory monocyte response to C. neoformans. The deletion of DAP12 improves fungal clearance and survival in a murine model of cryptococcosis, and DAP12-deficient monocyte-derived macrophages have better uptake and killing of the fungus. Additionally, the lungs of Dap12-/- mice have increased numbers of CD8+ T cells, cytotoxic adaptive immune cells that can be recruited and activated by macrophages and are important for the clearance of C. neoformans. Thus, DAP12 may be an important target for reversing the suppressive effects of C. neoformans on the fungicidal activity of inflammatory monocytes and their ability to prime CD8+ T cells. Our preliminary data indicate that this repressive DAP12 activity may be regulated by the binding of C. neoformans to the cell surface receptor triggering receptor expressed on myeloid cells 2 (TREM2) on monocyte-derived macrophages. The goal of this proposal is to further define this novel DAP12 signaling pathway. We hypothesize that C. neoformans induces formation of a TREM2-DAP12 signaling complex that coordinates effector molecules to inhibit the anti-cryptococcal defenses of inflammatory monocytes and CD8+ T cells, thereby subverting the host response to infection. The specific aims are to 1) determine the mechanism by which DAP12 signaling is initiated by C. neoformans, 2) define the signaling cascade that mediates the suppressive effects of DAP12 during infection, and 3) ascertain the role of inflammatory monocyte-intrinsic DAP12 in the regulation of CD8+ T cell responses to C. neoformans. Defining these mechanisms will deepen our understanding of host immunity to opportunistic fungi and inform new opportunities for immunomodulatory interventions against C. neoformans in vulnerable hosts.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Lena J Heung其他文献

Lena J Heung的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Lena J Heung', 18)}}的其他基金

DAP12 and the host response to cryptococcosis
DAP12 和宿主对隐球菌病的反应
  • 批准号:
    10275306
  • 财政年份:
    2021
  • 资助金额:
    $ 57.18万
  • 项目类别:
DAP12 and the host response to cryptococcosis
DAP12 和宿主对隐球菌病的反应
  • 批准号:
    10645193
  • 财政年份:
    2021
  • 资助金额:
    $ 57.18万
  • 项目类别:
Inflammatory monocytes and host control of cryptococcosis
炎症单核细胞和隐球菌病的宿主控制
  • 批准号:
    9902336
  • 财政年份:
    2017
  • 资助金额:
    $ 57.18万
  • 项目类别:
Inflammatory monocytes and host control of cryptococcosis
炎症单核细胞和隐球菌病的宿主控制
  • 批准号:
    10097959
  • 财政年份:
    2017
  • 资助金额:
    $ 57.18万
  • 项目类别:

相似海外基金

Mitophagy as a target for antifungal therapy
线粒体自噬作为抗真菌治疗的靶点
  • 批准号:
    488010
  • 财政年份:
    2023
  • 资助金额:
    $ 57.18万
  • 项目类别:
    Operating Grants
Enhanced Antifungal Therapy to Improve Survival in Early Disseminated Cryptococcal Infection
加强抗真菌治疗可提高早期播散性隐球菌感染的生存率
  • 批准号:
    10621009
  • 财政年份:
    2023
  • 资助金额:
    $ 57.18万
  • 项目类别:
Short Course Versus Standard Course Antifungal Therapy for Pediatric Candidemia: A Multi-Center Randomized Controlled Trial
儿童念珠菌血症的短期疗程与标准疗程抗真菌治疗:多中心随机对照试验
  • 批准号:
    10677753
  • 财政年份:
    2022
  • 资助金额:
    $ 57.18万
  • 项目类别:
Short Course Versus Standard Course Antifungal Therapy for Pediatric Candidemia: A Multi-Center Randomized Controlled Trial
儿童念珠菌血症的短期疗程与标准疗程抗真菌治疗:一项多中心随机对照试验
  • 批准号:
    10487627
  • 财政年份:
    2022
  • 资助金额:
    $ 57.18万
  • 项目类别:
(1-3)-beta-D-glucan guided early termination of antifungal therapy in ICU patients
(1-3)-β-D-葡聚糖指导 ICU 患者提前终止抗真菌治疗
  • 批准号:
    400727961
  • 财政年份:
    2018
  • 资助金额:
    $ 57.18万
  • 项目类别:
    Research Grants
Evaluation of CRAG screening with enhanced antifungal therapy for asymptomatic CRAG-positive persons
对无症状 CRAG 阳性者进行强化抗真菌治疗的 CRAG 筛查评估
  • 批准号:
    10341089
  • 财政年份:
    2018
  • 资助金额:
    $ 57.18万
  • 项目类别:
Directed Antifungal Therapy for HIV-associated Cryptococcal Meningitis
HIV 相关隐球菌性脑膜炎的定向抗真菌治疗
  • 批准号:
    8991829
  • 财政年份:
    2015
  • 资助金额:
    $ 57.18万
  • 项目类别:
Targeting hybrid histidine kinase for broad spectrum antifungal therapy
靶向混合组氨酸激酶进行广谱抗真菌治疗
  • 批准号:
    7936212
  • 财政年份:
    2009
  • 资助金额:
    $ 57.18万
  • 项目类别:
Targeting hybrid histidine kinase for broad spectrum antifungal therapy
靶向混合组氨酸激酶进行广谱抗真菌治疗
  • 批准号:
    7812372
  • 财政年份:
    2009
  • 资助金额:
    $ 57.18万
  • 项目类别:
Optimizing antifungal therapy for HIV-associated cryptococcal meningitis in Africa
优化非洲艾滋病毒相关隐球菌性脑膜炎的抗真菌治疗
  • 批准号:
    G0501476/1
  • 财政年份:
    2006
  • 资助金额:
    $ 57.18万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了